Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity

被引：0

作者：

Flinn, Ian

Hamlin, Paul A.

Strickland, Donald K.

Pandey, Anjali

Birrell, Matt

Coffey, Greg

Leeds, Janet

Curnutte, John T.

Burger, Jan Andreas

Wagner-Johnston, Nina D.

Patel, Manish R.

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Portola Pharmaceut Inc, San Francisco, CA USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[7] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8531

引用

页数：1